Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36;Geometric Mean Titers (GMT) of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 36;Percentage of Participants With Adverse Events of Special Interest (AESI) Until Day 50;Percentage of Participants With Any AE Leading to Discontinuation of Vaccination;Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 50;Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 50;Percentage of Participants With Serious Adverse Events (SAEs) Until Day 50;Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 50;Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination;Percentage of Participants With Solicited Local AEs for Six Subsequent Days Following Second Vaccination;Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following First Vaccination;Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following Second Vaccination;Percentage of Participants With Unsolicited AEs for 20 Days Following First Vaccination;Percentage of Participants With Unsolicited AEs for 27 Days Following Second Vaccination;Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36;Seroresponse Rate (SRR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36

Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36;Geometric Mean Titers (GMT) of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 36;Percentage of Participants With Adverse Events of Special Interest (AESI) Until Day 50;Percentage of Participants With Any AE Leading to Discontinuation of Vaccination;Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 50;Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 50;Percentage of Participants With Serious Adverse Events (SAEs) Until Day 50;Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 50;Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination;Percentage of Participants With Solicited Local AEs for Six Subsequent Days Following Second Vaccination;Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following First Vaccination;Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following Second Vaccination;Percentage of Participants With Unsolicited AEs for 20 Days Following First Vaccination;Percentage of Participants With Unsolicited AEs for 27 Days Following Second Vaccination;Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36;Seroresponse Rate (SRR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36

Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36;Geometric Mean Titers (GMT) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36;Percentage of Participants with Adverse Event of Special Interest (AESI) until Day 50;Percentage of Participants with Any AE Leading to Discontinuation of Vaccination;Percentage of Participants with Any AE Leading to Participant's Withdrawal from the Trial until Day 50;Percentage of Participants with Medically-Attended Adverse Events (MAAEs) until Day 50;Percentage of Participants with Reported Solicited Local Adverse Events (AEs) for 7 Days Following Each Vaccination;Percentage of Participants with SARS-CoV-2 Infection until Day 50;Percentage of Participants with Serious Adverse Events (SAE) until Day 50;Percentage of Participants with Solicited Systemic AEs for 7 Days Following Each Vaccination;Percentage of Participants with Unsolicited AEs for 49 Days Following First Vaccination (Day 1);Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36;Seroresponce Rate (SRR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36

Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36;Geometric Mean Titers (GMT) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36;Percentage of Participants with Adverse Event of Special Interest (AESI) until Day 50;Percentage of Participants with Any AE Leading to Discontinuation of Vaccination;Percentage of Participants with Any AE Leading to Participant's Withdrawal from the Trial until Day 50;Percentage of Participants with Medically-Attended Adverse Events (MAAEs) until Day 50;Percentage of Participants with Reported Solicited Local Adverse Events (AEs) for 7 Days Following Each Vaccination;Percentage of Participants with SARS-CoV-2 Infection until Day 50;Percentage of Participants with Serious Adverse Events (SAE) until Day 50;Percentage of Participants with Solicited Systemic AEs for 7 Days Following Each Vaccination;Percentage of Participants with Unsolicited AEs for 49 Days Following First Vaccination (Day 1);Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36;Seroresponce Rate (SRR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36